Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 3;9(5):e70137.
doi: 10.1002/hem3.70137. eCollection 2025 May.

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV)

Jean-Jacques Kiladjian  1 , Christoph Klade  2 , Pencho Georgiev  3 , Dorota Krochmalczyk  4 , Liana Gercheva-Kyuchukova  5 , Miklos Egyed  6 , Petr Dulicek  7 , Arpad Illes  8 , Halyna Pylypenko  9 , Lylia Sivcheva  10 , Jiří Mayer  11 , Vera Yablokova  12 , Kurt Krejcy  2 , Victoria Empson  2 , Hans C Hasselbalch  13 , Robert Kralovics  14 , Heinz Gisslinger  15 ; PROUD‐PV Study Group
Affiliations

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV)

Jean-Jacques Kiladjian et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

J. J. K. reports grants and personal fees from AOP Health, and personal fees from Novartis, BMS/Celgene, AbbVie, and PharmaEssentia. J. M. reports grants from AOP Health. R. K. reports personal fees from AOP Health, PharmaEssentia, Qiagen, and Novartis, and stock ownership in MyeloPro Diagnostics and Research. H. H. reports Data Monitoring Board honoraria from AOP Health and grants from Novartis. C. K., K. K., and V. E. report that they are employees of AOP Health. H. G. reports grants and personal fees from AOP Health and Novartis, and personal fees from BMS‐Pharma. The remaining authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Event‐free survival by molecular response at the last recorded time point. Event‐free survival was determined by Kaplan–Meier analysis of time to first event (events defined as thrombosis, progression to myelofibrosis, or death) according to molecular response status at the last available assessment.
Figure 2
Figure 2
Hazard ratio for events by JAK2V617F VAF over time. Hazard ratio (HR) for events according to JAK2V617F variant allele frequency (VAF), allowing for changing VAF over time, derived from an extended Cox proportional hazard model (events defined as thrombosis, progression to myelofibrosis, or death). Z denotes the JAK2V617F VAF value. Dotted lines represent the 95% confidence interval of the HR. Compared to a reference patient with a JAK2V617F VAF of 50%, a patient with a JAK2V617F VAF of 65% has an almost 2 times higher hazard of event (higher by 100%) and a patient with a JAK2V617F VAF of 30% has approximately half the hazard of event (lower by 50%).
See this image and copyright information in PMC

References

    1. Moliterno AR, Kaizer H, Reeves BN. JAK2V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141(16):1934‐1942. - PMC - PubMed
    1. Gotlib J. Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. Blood. 2022;139(19):2871‐2881. 10.1182/blood.2022015680 - DOI - PubMed
    1. Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534‐3544. - PMC - PubMed
    1. Guglielmelli P, Mora B, Gesullo F, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024;99:1550‐1559. - PubMed
    1. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa‐2b versus standard therapy for polycythaemia vera (PROUD‐PV and CONTINUATION‐PV): a randomised, non‐inferiority, phase 3 trial and its extension study. Lancet Haematol. Mar 2020;7(3):e196‐e208. 10.1016/S2352-3026(19)30236-4 - DOI - PubMed

LinkOut - more resources